menu
    • menu

    Company profile for PaxMedica

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders. Our lead programs are focused on two of the world’s most challenging conditions – Autism Spectrum Disorder (ASD) and Fragile X-associated Tremor / Ataxia (FXTAS). There are no FDA approved treatments for the core symptoms of ASD and no FDA approved treatments at all for FXTAS.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    PaxMedicaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    50 Tice Blvd, Suite A26 Woodcliff Lake, NJ 07677
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.paxmedica.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    PaxMedica Gets Patent for Suramin Intranasal Autism Treatment
    PaxMedica Gets Patent for Suramin Intranasal Autism Treatment

    14 Jan 2025

    // ACCESSWIRE

    https://www.accesswire.com/968065/paxmedica-announces-first-patent-allowance-for-suramin-intranasal-formulation-in-the-treatment-of-autism-spectrum-disorder-and-other-conditions

    ACCESSWIRE
    14 Jan 2025
    Share Share
    PaxMedica Files Nasdaq Delisting Appeal, Prepares For FDA PAX-101 Meeting
    PaxMedica Files Nasdaq Delisting Appeal, Prepares For FDA PAX-101 Meeting

    15 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/15/2882426/0/en/PaxMedica-Files-Nasdaq-Delisting-Appeal-Notice-and-Prepares-for-Upcoming-FDA-Meeting-on-PAX-101.html

    GLOBENEWSWIRE
    15 May 2024
    Share Share
    PaxMedica Provides Update, Advances PAX-101 Regulatory Strategy
    PaxMedica Provides Update, Advances PAX-101 Regulatory Strategy

    07 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/07/2876748/0/en/PaxMedica-Provides-Company-Update-and-Continues-to-Advance-PAX-101-Regulatory-Strategy.html

    GLOBENEWSWIRE
    07 May 2024
    Share Share
    PaxMedica To Provide Immediate PAX-101 IV Suramin Access
    PaxMedica To Provide Immediate PAX-101 IV Suramin Access

    23 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/23/2867666/0/en/PaxMedica-Responds-to-Emergency-Request-for-IV-Suramin-and-Commits-to-Provide-Immediate-Access-to-PAX-101.html

    GLOBENEWSWIRE
    23 Apr 2024
    Share Share
    PaxMedica Receives Emergency IV Suramin Request from African Health Ministry
    PaxMedica Receives Emergency IV Suramin Request from African Health Ministry

    16 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/16/2864119/0/en/PaxMedica-Receives-Emergency-Request-for-IV-Suramin-from-African-Health-Ministry-for-Use-in-Treating-Fatal-Sleeping-Sickness.html

    GLOBENEWSWIRE
    16 Apr 2024
    Share Share
    PaxMedica PAX-101 Milestone, Update on Potential NDA Filing
    PaxMedica PAX-101 Milestone, Update on Potential NDA Filing

    11 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/11/2861889/0/en/PaxMedica-Achieves-Key-Milestone-in-the-Development-of-PAX-101-And-Provides-Update-on-Potential-NDA-Submission.html

    GLOBENEWSWIRE
    11 Apr 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search